Biopharmaceutical Contract Manufacturing Market
Market Insights on Biopharmaceutical Contract Manufacturing covering sales outlook, demand forecast & up-to-date key trends
Biopharmaceutical Contract Manufacturing Market By Platform (Mammalian and Microbial), Product (Growth Factors, Interferons, Monoclonal Antibodies, Recombinant Hormones, Vaccines, Insulin and Others), Application (Clinical and Commercial) & Region - Forecast to 2022 - 2029
Biopharmaceutical Contract Manufacturing Market Snapshot (2022-2029)
[221 Pages Report] The global biopharmaceutical contract manufacturing market was valued at around US$ 8.4 Bn in 2021 and is anticipated to progress at a CAGR of 10.5% to reach US$ 18.7 Bn by 2029.
|
Data Points |
Market Insights |
|
Market Value 2021 |
US$ 8.4 Bn |
|
Market Value 2022 |
US$ 9.3 Bn |
|
Market Value 2029 |
US$ 18.7 Bn |
|
CAGR 2022-2029 |
10.5% |
|
Market Share of Top 5 Countries |
59.5% |
The continuous growth in life science research segment, increased R&D funding and development of various pharmaceutical products in various countries across the globe has added significantly to the growth of biopharmaceutical contract manufacturing market.
The biopharmaceutical contract manufacturing market holds less than 1% of the global contract manufacturing market in 2021 which is valued at nearly 2300 Bn.
In biopharmaceutical contract manufacturing market, a large number of local players as well as established players are significantly showing interest in either conducting biologic drug based research and development or performing bio-manufacturing processes in different countries, besides marketing their own products there.
Furthermore, the production of vaccines, biosimilars, recombinant proteins and monoclonal antibodies etc., using various technologies has been undertaken by utilizing outsourcing strategy by various manufacturers.
On the other hand, the virtual biotechnology companies with early clinical products uses outsourcing strategy wherein they collaborate with CMOs with smaller facilities for clinical supply at initial stage. Later on, they switch the production to another CMO who is capable of doing production in large batches and is enough experienced in moving products through the clinical phases. For early-stage projects, big biopharmaceuticals companies approach small CMOs. For commercial products, companies tie up with top tier CMO with expertise in vials and who have experience with the FDA.
To meet customer needs, biopharmaceutical companies are entering into various contract manufacturing agreements with contract manufacturing organization (CMO) and Contract manufacturing and development organization (CDMO).
Considering this, it is estimated for the biopharmaceutical contract manufacturing market to grow significantly over the forecast duration.
Let us know your requirement to get
100% FREE customization
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
10.62% |
|
H1, 2022 Projected |
10.62% |
|
H1, 2022 Outlook |
10.62% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 10 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 24 ↓ |
According to FMI, the biopharmaceuticals contract manufacturing market will drop in H1-2022(O) when compared with H1-2021 by 24 basis point share (BPS). Some of the main reasons for the deterioration in BPS are greater production time, higher costs, risk of intellectual property exchange, and lack of communication channels between biopharma companies and contract manufacturing organizations.
The growth rates and development possibilities of the global biopharmaceuticals contract manufacturing market are compared by FMI. The market is influenced by quality control, drug stability studies, regulations, and the impact of macro and industrial variables. This, in turn, is expected to affect the market growth rate in the H1-2022 outlook period to show a dip by nearly 10 BPS when compared with H1-2022 projected period.
While the biopharmaceutical industry has made significant progress, the contract manufacturing and development organisation (CDMO), which develops and manufactures drug substances for biopharmaceutical companies, has grown at the same time, demonstrating a pharmaceutical industry ecosystem that is a horizontal division model of drug research by pharmaceutical and biotech organisations, along with drug manufacture by CDMOs, and is a key driving factor in this sector.
Reduction in sourcing and production costs conversely provide a lucrative growth impact on the biopharmaceuticals contract manufacturing market.
Sales Analysis of Biopharmaceutical Contract Manufacturing from 2012 to 2021 Vs Market Outlook for 2022 to 2029
Sales of biopharmaceutical contract manufacturing market grew at a CAGR of 9.5% between 2012 and 2021.
Biopharmaceuticals contract manufacturing firms play an important role in commercial manufacturing as well as late clinical phase of biologics production. Big pharma companies have limited capacity for biologics production. This incapability leads towards outsourcing of biologics production, which is leading to the growth in the biopharmaceutical contract manufacturing market.
The growth of the biopharmaceutical contact manufacturing industry globally is also driven by strong biologics pipeline that fuel the demand for these CMOs (Contact Manufacturing Organizations). A large number of biotech patents are applied every year and this tends to be growing at 23% annually. Nearly 1500 biomolecules are currently under clinical trials, targeting more than 100 types of diseases, the biologics have shown two times higher success rate as compared to small-molecule products. The current biologics-development pipeline thus, supports an outlook of continued healthy growth.
The market is expected to expand at a considerable growth rate over the next seven years at a CAGR of close to 10.5% from 2022 to 2029.
What are the Key Opportunities Biopharmaceutical Contract Manufacturing?
Key players acting in this market are opting for inorganic growth strategies to boost their earnings and grow market share by way of providing integrated solutions to customers. While few companies are undertaking merger and acquisitions to grow their consumer base, others are involved in aggressive expansion of their product/services/capabilities through strategic alliances. Furthermore, integration strategy of acquiring manufacturing facilities from large pharmaceutical companies is being adopted as another key strategy.
For instance, In July 2020, Fujifilm acquired the Biogen’s large-scale bio-manufacturing facility for US$ 890 million. Similarly, In July 2021, AbbVie Company acquired Allergen. This acquisition helped AbbVie expand its global operations in order to supply end-to-end drug substance and product to manufacturing partners of AbbVie. The contract manufacturing services offers topical creams and ointments, biologics fill-finish, sterile ophthalmic ointments and custom API.
Additionally, many organizations are focusing on reducing the overall operational cost associated with R&D and commercialization of a drug, by looking out for outsourcing options to CMOs. Outsourcing at a later stage of clinical development through identification and appointment of a strategic partner could improve efficiencies all along the value chain.
The CDMO & CMO business model is emerging as a key differentiating strategy which is transforming the pharmaceutical ecosystem, disrupting drug development and manufacturing technologies and providing major growth opportunities in high potency and biopharmaceuticals manufacturing. Thus, providing for long-term profitability of CMOs at the global level.
These developments are thus, set to provide the biopharmaceutical contract manufacturing market with profitable prospects over the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Factors Restraining Demand for Biopharmaceutical Contract Manufacturing?
Biopharmaceuticals manufacturing capacity is one of the important factors in the growth of the market. Manufacturing of drugs in bulk volumes requires facilities to have large scale plants with huge capacity and big funding. Globally, biopharma companies have spent billions in just the past few years on new plants and equipment. Much of that has been in tax havens, like Ireland and Singapore, and in emerging markets. About a quarter of the projects have been in the US.
Additionally, development of a new plants takes nearly 4 years to design, build and qualify, while costing anywhere between US$ 250 million to US$ 2 billion, which is too high as compared to small scale pants and industries. Also, with availability of limited yet traditional facilities, it is not enough and also too old to develop any modern drugs. Thus, limited CMO facility together with the need for huge capital investment poses a major restraining factor for the growth of this market.
Another major factor impacting this market is the changing regulatory dynamics around the globe. Global regulatory policies, tightening regime of inspection and supply chain security related issues across countries impacts largely on the cost of final products and ultimately makes the market entry for new players a costly decision due to financial constraints along with the aforementioned factors.
The increasing complexity of biopharmaceuticals operations and the biopharmaceuticals supply chain has already stretched the current production programs across industries. Many players are thus, constantly failing to deliver to the market. All these factors are expected to hinder the growth of the biopharmaceutical contract manufacturing market over the forecast duration globally.
Country-wise Insights
What Makes the U.S. the Largest Market for Biopharmaceutical Contract Manufacturing?
The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period. The growth of this market is driven by the high corporate venture capital investments which are helping to advance biotechnology R&D, strong biologics pipeline fuelling the demand for the CMOs and establishment of key manufacturers & research institutes with dedicated programs for the contract manufacturing organizations.
Why is Germany Considered a Lucrative Market for Biopharmaceutical Contract Manufacturing?
Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option. Thus, more research and clinical trials in biopharmaceuticals to reduce the cost and focus on outsourcing of most research activities is raising the demand for biopharmaceutical contract manufacturing market in Germany.
What Makes China an Emerging Market for Biopharmaceutical Contract Manufacturing?
China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth, including seeking the opportunities to collaborate/partner with the local organizations which is helping this region to emerge and grow over the forecast period.
What is the Outlook for India Regarding Biopharmaceutical Contract Manufacturing?
In 2021, India held a 30.4% share in the global Biopharmaceutical Contract Manufacturing market and is projected to expand at a CAGR of 11.9% from 2022 to 2029. India projects a significant growth in the global biopharmaceutical contract manufacturing market owing to increase in the investments in research and development area, expansion in the offerings of the services and increase in the outsourcing processes by different biopharmaceutical industries.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-wise Insights
Which Biopharmaceutical Contract Manufacturing Platform is Driving Market Growth?
Mammalian-based segment hold the largest market share of 72.8% in 2021 and is projected to grow over the forecast period, with CAGR of about 12.3% due to higher efficiency and less time-consuming effort. Mammalian based cell culture such as Chinese Hamster Ovary cells (CHO) and recombinant monoclonal antibodies have been used for the production of biopharmaceuticals in large quantities as compared to other platforms.
Which Biopharmaceutical Contract Manufacturing Product is Driving Market Growth?
Monoclonal Antibodies products project a lucrative growth at a CAGR of 11.6% till the end of the forecast period, with a market share of around 50.0% in 2021. Increasing prevalence of metabolic diseases and cancer is helping to increase the revenue share of the recombinant protein and insulin segment of the monoclonal antibodies due to increased usage in the research field.
Why is Commercial application being Widely Adopted Application in the Biopharmaceutical Contract Manufacturing Market?
Commercial application enjoys a revenue share of 78.7% in the global biopharmaceutical contract manufacturing market in 2021. Commercial segment revenue share is expected to increase further over the forecast duration with a growth rate of 10.9% due to the increasing biologic drugs demand and large scale up facility of contract manufacturing organizations.
Which Therapeutic Area is Largely of Focus in the Biopharmaceutical Contract Manufacturing Market?
Oncology holds a revenue share of 20.9% in 2021 and are projected to grow over the forecast period with CAGR of 13.6%. The segment holds the largest revenue share due to the increasing incidences and prevalence of the targeted diseases in the oncology segment all over the Globe. Additionally, large number of clinical research activities to develop new therapeutic options and involvement of large number of manufacturers introducing novel product lines in this field further adds to the growth of this market.
Competitive Landscape
Leading contract manufacturing organizations are focusing on geographical expansion to gain high revenue & expand their sales footprint in emerging countries by acquisition of local market players.
Strategic divestitures, collaborations, exclusive partnership agreements and research sponsorship are the key strategies adopted by manufacturers to increase the product sales in different geographies.
- In 2021, Lonza Group Ag, disclosed its highest sale after selling Lonza Speciality Ingredients to Bain Capital Private Equity for $4.4B.
- In November 2021, Abzena limited, a partner research organization for integrated discovery of cGMP and a manufacturer of biopharmaceuticals solutions collaborated with BiVictriX Therapeutics plc, a biotechnology company to manufacture the BiVictriX’s antibody-drug conjugates (ADC).
- In September 2021 Novasep Company did an exclusive partnership with PharmaZell. The partnership is focussed to develop, manufacture and expand, complex small molecules and ADCs at a global scale.
Similarly, recent developments related to companies of biopharmaceuticals contract manufacturing have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope as per Biopharmaceutical Contract Manufacturing Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2022-2029 |
|
Historical Data Available for |
2012-2021 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan and Middle East & Africa |
|
Key Countries Covered |
US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, North Africa, GCC Countries, Turkey, and South Africa |
|
Key Market Segments Covered |
Platform, Product, Application, Therapeutic area, and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered in Biopharmaceutical Contract Manufacturing Industry Research
By Platform Type:
- Mammalian Based
- Microbial Based
By Product Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Application Type:
- Clinical
- Commercial
By Therapeutic Area Type:
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- Middle East and Africa (MEA)
Frequently Asked Questions
The global biopharmaceutical contract manufacturing market is worth US$ 9.28 Bn in 2021 and is estimated to grow 2 times over the forecast duration.
The biopharmaceutical contract manufacturing market is expected to reach US$ 18.65 Bn by the end of 2029, with sales revenue expected to register 10.5% CAGR.
Growing technical advancements, strategic research collaborations, acquisitions & expansion by outsourcing of biopharmaceuticals manufacturing and accelerating product adoption rate are some of the key trends being witnessed in this marketplace.
The U.S., China, India, Japan, Germany are expected to drive demand in biopharmaceutical contract manufacturing market.
North America is one of the key markets for biopharmaceutical contract manufacturing, with the U.S. expected to account for nearly 91.0% of the North American market during the forecast period.
Demand for biopharmaceutical contract manufacturing in Eastern Europe is expected to register growth of 10% over the next seven years.
Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), Baxter Pharmaceutical Solutions LLC (Baxter Inc.), AbbVie Contract Manufacturing (AbbVie Inc.), Samsung Biologics Co. Ltd. , ProBioGen AG , Pfizer Centre Source Ltd (Pfizer Inc.), Novasep , Biomeva GmbH, Kbi Biopharma Inc, Rentschler Biotechnologie GmbH and Ajinomoto Althea Inc., (Ajinomoto Co., Inc.) are the key
Table of Content
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. Analysis and Recommendations
2. Market Introduction
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Regulatory Overview
4. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Opportunity Assessment, 2022-2029
4.1. Historical Market Value (US$ Mn) Analysis, 2012-2021
4.2. Current and Future Market Value (US$ Mn) Projections, 2022-2029
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Incremental Opportunity Analysis
4.2.3. Market Value Comparison
5. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Platform
5.1. Introduction / Key Findings
5.2. Historical Market Size (US$ Mn) Analysis By Platform, 2012–2021
5.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Platform, 2022-2029
5.3.1. Mammalian
5.3.2. Microbial
5.4. Market Attractiveness Analysis By Platform
6. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Product
6.1. Introduction / Key Findings
6.2. Historical Market Size (US$ Mn) Analysis By Product, 2012–2021
6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2029
6.3.1. Growth Factors
6.3.2. Interferon’s
6.3.3. Monoclonal Antibodies
6.3.4. Recombinant Hormones
6.3.5. Vaccines
6.3.6. Insulin
6.3.7. Others
6.4. Market Attractiveness Analysis By Product
7. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Application
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Application, 2012–2021
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2029
7.3.1. Clinical
7.3.2. Commercial
7.4. Market Attractiveness Analysis By Application
8. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Therapeutic Area
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2012–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2022-2029
8.3.1. Autoimmune Diseases
8.3.2. Oncology
8.3.3. Metabolic Diseases
8.3.4. Ophthalmology
8.3.5. Cardiovascular Diseases
8.3.6. Infectious Diseases
8.3.7. Neurology
8.3.8. Respiratory Disorders
8.3.9. Others
8.4. Market Attractiveness Analysis By Therapeutic Area
9. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Region
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021
9.3. Current and Future Market Size (US$ Mn) and Forecast By Region, 2022-2029
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. APEJ
9.3.6. Japan
9.3.7. Middle East & Africa
9.4. Market Attractiveness Analysis By Region
10. North America Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
10.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
10.4.1. By Country
10.4.1.1. U.S.
10.4.1.2. Canada
10.4.2. By Platform
10.4.3. By Product
10.4.4. By Application
10.4.5. By Therapeutic Area
10.5. Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Platform
10.5.3. By Product
10.5.4. By Application
10.5.5. By Therapeutic Area
10.6. Key Market Participants - Intensity Mapping
11. Latin America Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029
11.1. Introduction
11.2. Regional Market Dynamics
11.2.1. Drivers
11.2.2. Restraints
11.2.3. Trends
11.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
11.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
11.4.1. By Country
11.4.1.1. Mexico
11.4.1.2. Brazil
11.4.1.3. Rest of Latin America
11.4.2. By Platform
11.4.3. By Product
11.4.4. By Application
11.4.5. By Therapeutic Area
11.5. Market Attractiveness Analysis
11.5.1. By Platform
11.5.2. By Product
11.5.3. By Application
11.5.4. By Therapeutic Area
11.6. Key Market Participants - Intensity Mapping
12. Western Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029
12.1. Introduction
12.2. Regional Market Dynamics
12.2.1. Drivers
12.2.2. Restraints
12.2.3. Trends
12.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
12.4.1. By Country
12.4.1.1. U.K.
12.4.1.2. Germany
12.4.1.3. France
12.4.1.4. Italy
12.4.1.5. Spain
12.4.1.6. BENELUX
12.4.1.7. Nordic
12.4.1.8. Rest of Western Europe
12.4.2. By Platform
12.4.3. By Product
12.4.4. By Application
12.4.5. By Therapeutic Area
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Platform
12.5.3. By Product
12.5.4. By Application
12.5.5. By Therapeutic Area
12.6. Key Market Participants - Intensity Mapping
13. Eastern Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029
13.1. Introduction
13.2. Regional Market Dynamics
13.2.1. Drivers
13.2.2. Restraints
13.2.3. Trends
13.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
13.4.1. By Country
13.4.1.1. Russia
13.4.1.2. Poland
13.4.1.3. Rest of Eastern Europe
13.4.2. By Platform
13.4.3. By Product
13.4.4. By Application
13.4.5. By Therapeutic Area
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Platform
13.5.3. By Product
13.5.4. By Application
13.5.5. By Therapeutic Area
13.6. Key Market Participants - Intensity Mapping
14. APEJ Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029
14.1. Introduction
14.2. Regional Market Dynamics
14.2.1. Drivers
14.2.2. Restraints
14.2.3. Trends
14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
14.4.1. By Country
14.4.1.1. China
14.4.1.2. India
14.4.1.3. Australia & New Zealand
14.4.1.4. ASEAN
14.4.1.5. South Korea
14.4.1.6. Rest of APEJ
14.4.2. By Platform
14.4.3. By Product
14.4.4. By Application
14.4.5. By Therapeutic Area
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Platform
14.5.3. By Product
14.5.4. By Application
14.5.5. By Therapeutic Area
14.6. Key Market Participants - Intensity Mapping
15. Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029
15.1. Introduction
15.2. Regional Market Dynamics
15.2.1. Drivers
15.2.2. Restraints
15.2.3. Trends
15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
15.4.1. By Platform
15.4.2. By Product
15.4.3. By Application
15.4.4. By Therapeutic Area
15.5. Market Attractiveness Analysis
15.5.1. By Platform
15.5.2. By Product
15.5.3. By Application
15.5.4. By Therapeutic Area
15.6. Key Market Participants - Intensity Mapping
16. Middle East and Africa Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029
16.1. Introduction
16.2. Regional Market Dynamics
16.2.1. Drivers
16.2.2. Restraints
16.2.3. Trends
16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
16.4.1. By Country
16.4.1.1. GCC Countries
16.4.1.2. Turkey
16.4.1.3. North Africa
16.4.1.4. South Africa
16.4.1.5. Rest of Middle East & Africa
16.4.2. By Platform
16.4.3. By Product
16.4.4. By Application
16.4.5. By Therapeutic Area
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Platform
16.5.3. By Product
16.5.4. By Application
16.5.5. By Therapeutic Area
16.6. Key Market Participants - Intensity Mapping
17. Competition Landscape
17.1. Competition Dashboard
17.2. Company Deep Dive
17.2.1. Catalent Inc.
17.2.1.1. Overview
17.2.1.2. Product Overview
17.2.1.3. Key Financials
17.2.1.4. Key Developments
17.2.1.5. SWOT Analysis
17.2.1.6. Strategic Overview
17.2.2. Lonza Group Ag
17.2.2.1. Overview
17.2.2.2. Product Overview
17.2.2.3. Key Financials
17.2.2.4. Key Developments
17.2.2.5. SWOT Analysis
17.2.2.6. Strategic Overview
17.2.3. Patheon N.V. (Thermo Fisher Scientific Inc.)
17.2.3.1. Overview
17.2.3.2. Product Overview
17.2.3.3. Key Financials
17.2.3.4. Key Developments
17.2.3.5. SWOT Analysis
17.2.3.6. Strategic Overview
17.2.4. Abzena Plc.
17.2.4.1. Overview
17.2.4.2. Product Overview
17.2.4.3. Key Financials
17.2.4.4. Key Developments
17.2.4.5. SWOT Analysis
17.2.4.6. Strategic Overview
17.2.5. Sandoz International GmbH (Novartis AG)
17.2.5.1. Overview
17.2.5.2. Product Overview
17.2.5.3. Key Financials
17.2.5.4. Key Developments
17.2.5.5. SWOT Analysis
17.2.5.6. Strategic Overview
17.2.6. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
17.2.6.1. Overview
17.2.6.2. Product Overview
17.2.6.3. Key Financials
17.2.6.4. Key Developments
17.2.6.5. SWOT Analysis
17.2.6.6. Strategic Overview
17.2.7. Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
17.2.7.1. Overview
17.2.7.2. Product Overview
17.2.7.3. Key Financials
17.2.7.4. Key Developments
17.2.7.5. SWOT Analysis
17.2.7.6. Strategic Overview
17.2.8. AbbVie Contract Manufacturing (AbbVie Inc.)
17.2.8.1. Overview
17.2.8.2. Product Overview
17.2.8.3. Key Financials
17.2.8.4. Key Developments
17.2.8.5. SWOT Analysis
17.2.8.6. Strategic Overview
17.2.9. Samsung Biologics Co. Ltd.
17.2.9.1. Overview
17.2.9.2. Product Overview
17.2.9.3. Key Financials
17.2.9.4. Key Developments
17.2.9.5. SWOT Analysis
17.2.9.6. Strategic Overview
17.2.10. ProBioGen AG
17.2.10.1. Overview
17.2.10.2. Product Overview
17.2.10.3. Key Financials
17.2.10.4. Key Developments
17.2.10.5. SWOT Analysis
17.2.10.6. Strategic Overview
17.2.11. Pfizer Centre Source Ltd (Pfizer Inc.)
17.2.11.1. Overview
17.2.11.2. Product Overview
17.2.11.3. Key Financials
17.2.11.4. Key Developments
17.2.11.5. SWOT Analysis
17.2.11.6. Strategic Overview
17.2.12. Novasep
17.2.12.1. Overview
17.2.12.2. Product Overview
17.2.12.3. Key Financials
17.2.12.4. Key Developments
17.2.12.5. SWOT Analysis
17.2.12.6. Strategic Overview
17.2.13. Biomeva GmbH
17.2.13.1. Overview
17.2.13.2. Product Overview
17.2.13.3. Key Financials
17.2.13.4. Key Developments
17.2.13.5. SWOT Analysis
17.2.13.6. Strategic Overview
17.2.14. Kbi Biopharma Inc
17.2.14.1. Overview
17.2.14.2. Product Overview
17.2.14.3. Key Financials
17.2.14.4. Key Developments
17.2.14.5. SWOT Analysis
17.2.14.6. Strategic Overview
17.2.15. Rentschler Biotechnologie GmbH
17.2.15.1. Overview
17.2.15.2. Product Overview
17.2.15.3. Key Financials
17.2.15.4. Key Developments
17.2.15.5. SWOT Analysis
17.2.15.6. Strategic Overview
17.2.16. Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)
17.2.16.1. Overview
17.2.16.2. Product Overview
17.2.16.3. Key Financials
17.2.16.4. Key Developments
17.2.16.5. SWOT Analysis
17.2.16.6. Strategic Overview
18. Assumption and Acronyms Used
19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Growth Comparison
Table 02: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 03: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Product
Table 04: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis- and Opportunity Assessment 2012–2029, By Application
Table 05: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis- and Opportunity Assessment 2012–2029, By Therapeutic Area
Table 06: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Region
Table 07: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 08: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 09: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product
Table 10: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area
Table 11: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 12: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 13: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 14: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product
Table 15: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area
Table 16: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 17: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 18: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 19: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product
Table 20: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area
Table 21: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 22: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 23: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 24: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product
Table 25: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area
Table 26: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 27: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 28: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 29: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product
Table 30: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area
Table 31: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 32: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 33: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 34: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product
Table 35: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area
Table 36: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 37: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type
Table 38: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product
Table 39: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area
Table 40: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Biopharmaceutical Contract Manufacturing Market Revenue Share by Platform, 2022E & 2029F
Figure 2: Biopharmaceutical Contract Manufacturing Market Revenue Share by Application, 2022E & 2029F
Figure 3: Biopharmaceutical Contract Manufacturing Market Revenue Share by Product, 2022E & 2029F
Figure 4: Biopharmaceutical Contract Manufacturing Market Revenue Share by Therapeutic Area, 2022E & 2029F
Figure 05: Global Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 06: Global Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 07: Global Biopharmaceutical Contract Manufacturing Market Absolute $ Opportunity, 2022 - 2029
Figure 08: Comparison August 2017 and December 2022, Y-o-Y Forecast
Figure 09: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Platform Type, 2022 & 2029
Figure 10: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Platform Type, 2022-2029
Figure 11: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 12: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Product, 2022 & 2029
Figure 13: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Product, 2022-2029
Figure 14: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 15: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Application, 2022 & 2029
Figure 16: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Application, 2022-2029
Figure 17: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 18: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Therapeutic Area, 2022 & 2029
Figure 19: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Therapeutic Area, 2022-2029
Figure 20: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 21: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Region, 2022 & 2029
Figure 22: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Region, 2022-2029
Figure 23: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Region, 2022-2029
Figure 24: North America Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)
Figure 25: North America Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)
Figure 26: North America Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)
Figure 27: North America Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)
Figure 28: North America Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)
Figure 29: North America Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 30: North America Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 31: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 32: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 33: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 34: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 35: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029
Figure 36: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)
Figure 37: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)
Figure 38: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)
Figure 39: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)
Figure 40: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)
Figure 41: Latin America Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 42: Latin America Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 43: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 44: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 45: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 46: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 47: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029
Figure 48: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)
Figure 49: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)
Figure 50: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)
Figure 51: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)
Figure 52: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)
Figure 53: Western Europe Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 54: Western Europe Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 55: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 56: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 57: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 58: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 59: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029
Figure 60: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)
Figure 61: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)
Figure 62: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)
Figure 63: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)
Figure 64: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)
Figure 65: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 66: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 67: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 68: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 69: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 70: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 71: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029
Figure 72: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)
Figure 73: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)
Figure 74: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)
Figure 75: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)
Figure 76: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)
Figure 77: APEJ Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 78: APEJ Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 79: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 80: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 81: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 82: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 83: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029
Figure 84: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)
Figure 85: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)
Figure 86: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)
Figure 87: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)
Figure 88: Japan Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 89: Japan Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 90: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 91: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 92: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 93: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 94: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)
Figure 95: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)
Figure 96: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)
Figure 97: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)
Figure 98: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)
Figure 99: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021
Figure 100: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029
Figure 101: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029
Figure 102: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029
Figure 103: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029
Figure 104: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029
Figure 105: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
